MarketPulse
T

$TPST

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest's Dual-Targeting CAR-T Shows Promise as Clinical Data Update Looms

Tempest Therapeutics will present updated TPST-2003 CAR-T trial data at ISCT 2026, building on earlier 100% complete response rates in multiple myeloma patients.
TPSTclinical trialmultiple myeloma
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Tempest Advances CAR-T Program With Manufacturing Deal Ahead of 2026 FDA Filing

Tempest Therapeutics partners with Cincinnati Children's for TPST-2003 manufacturing, targeting U.S. registrational study launch in 2026 following strong interim trial results.
TPSTclinical trialmultiple myeloma